CFTR Protein Repair Therapy in Cystic Fibrosis;Tratamientos reparadores de la proteína CFTR en la fibrosis quística

Archivos de Bronconeumologia

Volumn 50, Issue 4, 2014, Pages 146-150

  Quintana Gallego, Esther ^a,b   Delgado Pecellín, Isabel ^a   Calero Acuña, Carmen ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Ataluren; CFTR corrector; CFTR modulator; CFTR potentiator; Cystic fibrosis transmembrane conductance regulator; Ivacaftor; Lumacaftor

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LUMACAFTOR; AMINOPHENOL DERIVATIVE; N-(2,4-DI-TERT-BUTYL-5-HYDROXYPHENYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE; QUINOLONE DERIVATIVE;

CYSTIC FIBROSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; GENE MUTATION; GENE THERAPY; HUMAN; SHORT SURVEY; STOP CODON; DRUG EFFECTS; GENETICS; MOLECULARLY TARGETED THERAPY; MUTATION;

AMINOPHENOLS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; QUINOLONES;

EID: 85047699188     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2014.03.002     Document Type: Short Survey

References (45)

1. Finishing the euchromatic sequence of the human, genome. Nature 2004, 431:931-945. International Human Genome Sequencing Consortium.
2. Chadwell K. Clinical practice on the horizon: Personalized medicine. Clin Nurse Spec 2013, 27:36-43.
3. Ideker T., Galitski T., Hood L. A new approach to decoding life: Systems biology. Annu Rev Genomics Hum Genet 2001, 2:343-372.
4. Ferraldeschi R., Newman W.G. Pharmacogenetics and pharmacogenomics: A clinical reality. Ann Clin Biochem 2011, 48:410-417.
5. Tian Q., Price N.D., Hood L. Systems cancer medicine: Towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med 2012, 271:111-121.
6. Castellani C., Macek M., Cassiman J.J., Duff A., Massie J., ten Kate L.P., et al. Benchmarks for cystic fibrosis carrier screening: A European consensus document. J Cyst Fibros 2010, 9:165-178.
7. Gartner S., Cobos N. [Neonatal screening for cystic fibrosis]. An Pediatr (Barc) 2009, 71:481-482.
8. Mogayzel P.J., Naureckas E.T., Robinson K.A., Mueller G., Hadjiliadis D., Hoag J.B., et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013, 187:680-689.
9. Patient registry annual data report 2011, Cystic Fibrosis Foundation, Bethesda, Maryland.
10. Elborn J.S. Personalised medicine for cystic fibrosis: Treating the basic defect. Eur Respir Rev 2013, 22:3-5.
11. Derichs N. Targeting a genetic defect: Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Eur Respir Rev 2013, 22:58-65.
12. Griesenbach U., Alton E.W. Progress in gene and cell therapy for cystic fibrosis lung disease. Curr Pharm Des 2012, 18:642-662.
13. Boyle M.P., de Boeck K. A new era in the treatment of cystic fibrosis: Correction of the underlying CFTR defect. Lancet Infect Dis 2013, 1:158-163.
14. Repeated application of gene therapy in CF patients. [consultado 15 Sep 2013]. Disponible en: http://www.clinicaltrials.gov/ct2/show/NCT01621867.
15. Berwouts S., Morris M.A., Girodon E., Schwarz M., Stuhrmann M., Dequeker E. Mutation nomenclature in practice: Findings and recommendations from the cystic fibrosis external quality assessment scheme. Hum Mutat 2011, 32:1197-1203.
16. Cystic Fibrosis Mutation Database. [consultado 15 Sep 2013]. Disponible en: http://www.genet.sickkids.on.ca/app.
17. Rowe S.M., Miller S., Sorscher E.J. Cystic fibrosis. N Engl J Med 2005, 352:1992-2001.
18. Howard M., Frizzell R.A., Bedwell D.M. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996, 2:467-469.
19. Bedwell D.M., Kaenjak A., Benos D.J., Bebok Z., Bubien J.K., Hong J., et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997, 3:1280-1284.
20. Clancy J.P., Bebök Z., Ruiz F., King C., Jones J., Walker L., et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001, 163:1683-1692.
21. Sermet-Gaudelus I., Renouil M., Fajac A., Bidou L., Parbaille B., Pierrot S., et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med 2007, 5:5.
22. Welch E.M., Barton E.R., Zhuo J., Tomizawa Y., Friesen W.J., Trifillis P., et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007, 447:87-91.
23. Kerem E., Hirawat S., Armoni S., Yaakov Y., Shoseyov D., Cohen M., et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: A prospective phase ii trial. Lancet 2008, 372:719-727.
24. Sermet-Gaudelus I., Boeck K.D., Casimir G.J., Vermeulen F., Leal T., Mogenet A., et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010, 182:1262-1272.
25. Wilschanski M., Miller L.L., Shoseyov D., Blau H., Rivlin J., Aviram M., et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011, 38:59-69.
26. Konstan M., Accurso F., de Boeck K., Kerem E., Rowe S., Sermet-Gaudelus I., et al. Targeting class 1 mutations: Update on ataluren as a promising treatment for nonsense mutation in CF. Pediatr Pulmonol 2012, S35:108-109.
27. Van Goor F., Hadida S., Grootenhuis P.D., Burton B., Stack J.H., Straley K.S., et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 2011, 108:18843-18848.
28. Clancy J.P., Rowe S.M., Accurso F.J., Aitken M.L., Amin R.S., Ashlock M.A., et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012, 67:12-18.
29. Flume P.A., Liou T.G., Borowitz D.S., Li H., Yen K., Ordoñez C.L., et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012, 142:718-724.
30. Boyle M.P., Bell S., Konstan M., McColley S.A., Kang L., Patel N., et al. VX-809 (lumacaftor) co-administered with the oral potentiator ivacaftor improved CFTR and lung function in F508del homozygous patients: Phase II study results. Pediatr Pulmonol 2012, 47(Suppl 35):S315. The investigational CFTR corrector.
31. A study of lumacaftor in combination with ivacaftor in cysticfFibrosis subjects aged 12 years and older who are homozygous for the F508del-CFTR mutation (TRAFFIC). [consultado 15 Sep 2013]. Disponible en: clinicaltrials.gov/ct2/show/NCT01807923.
32. A study of lumacaftor in combination with ivacaftor in cystic fibrosis subjects aged 12 years and older who are homozygous for the F508del-CFTR mutation (TRANSPORT). [consultado 15 Sep 2013]. Disponible en: http://clinicaltrials.gov/ct2/show/NCT01807949.
33. Study of VX-661 alone and in combination with VX-770 in subjects homozygous to the F508del-CFTR mutation. [consultado 15 Sep 2013]. Disponible en: clinicaltrials.gov/ct2/show/NCT01531673.
34. Van Goor F., Hadida S., Grootenhuis P.D., Burton B., Stack J.H., Straley K.S., et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 2009, 106:18825-18830.
35. Accurso F.J., Rowe S.M., Clancy J.P., Boyle M.P., Dunitz J.M., Durie P.R., et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010, 363:1991-2003.
36. Ramsey B.W., Davies J., McElvaney N.G., Tullis E., Bell S.C., Dřevínek P., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011, 365:1663-1672.
37. Davies J.C., Wainwright C.E., Canny G.J., Chilvers M.A., Howenstine M.S., Munck A., et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013, 187:1219-1225.
38. Study of VX-770 in cystic fibrosis subjects. [consultado 15 Sep 2013]. Disponible en: clinicaltrials.gov/ct2/show/study/NCT01117012.
39. McKone E.L.H., Yen K., Davies J.C. Long-term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation. J Cyst Fibros 2012, 11(Suppl1):S13.
40. Study of ivacaftor in cystic fibrosis subjects 2 through 5 years of age with a CTFR gating mutation. [consultado 15 Sep 2013]. Disponible en: clinicaltrials.gov/ct2/show/NCT01705145.
41. Yu H., Burton B., Huang C.J., Worley J., Cao D., Johnson Jr.J.P., et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012, 11:237-245.
42. Study of ivacaftor in subjects with cystic fibrosis who have a non-G551D CFTR gating mutation (KONNECTION). [consultado 15 Sep 2013]. Disponible en: clinicaltrials.gov/ct2/show/NCT01614470.
43. Rollover study of ivacaftor in subjects with cystic fibrosis and a non G551D CFTR mutation (KONTINUE). [consultado 15 Sep 2013]. Disponible en: clinicaltrials.gov/ct2/show/NCT01707290.
44. Study of ivacaftor in subjects with cystic fibrosis who have the R117H-CFTR mutation (KONDUCT). [consultado 15 Sep 2013]. Disponible en: clinicaltrials.gov/ct2/show/NCT01614457.
45. G551D observational study (GOAL). [consultado 15 Sep 2013]. Disponible en: clinicaltrials.gov/ct2/show/NCT01521338.